Navigation Links
GenVec Reports Third Quarter 2010 Financial Results
Date:11/8/2010

GAITHERSBURG, Md., Nov. 8, 2010 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) today announced its financial results for the third quarter ended September 30, 2010.  

GenVec reported a net loss of $2.4 million ($0.02 per share) for the three months ended September 30, 2010 compared to a net loss of $3.6 million ($0.04 per share) in the comparable quarter of 2009. For the nine months ended September 30, 2010, GenVec's net loss was $11.3 million ($0.09 per share) compared to a net loss of $14.1 million ($0.15 per share) for the nine months ended September 30, 2009.  

Revenues for the three-month and nine-month periods ended September 30, 2010 were $5.2 million and $11.3 million, respectively, representing increases of 76 percent and 7 percent as compared to $2.9 million and $10.5 million in the comparable prior year periods. The increase for the three and nine-month periods ended September 30, 2010 is primarily due to increased revenue associated with our hearing loss and balance disorder program and collaboration with Novartis that began in January 2010.  During the three and nine-month periods ended September 30, 2010 our revenues for this program increased $3.1 million and $4.5 million, respectively.  Partially offsetting the increase in revenue associated with our hearing loss and balance disorder program is lower revenue under both the foot and mouth disease (FMD) and HIV programs, a result of the decreased work scope and effort in 2010 as compared to the 2009 periods.  Revenue for the three and nine-month periods ended September 30, 2010 associated with our FMD program decreased $267,000 and $2.4 million, respectively, as compared to the prior year periods.  Revenue for the three and nine-month periods ended September 30, 2010 associated with our HIV program decreased $0.7 million and $1.6 million, respectively, as compared to the prior year periods.  

Operating expenses were $7.5 million and $22.6 million for the three-month and nine-month periods ended September 30, 2010, respectively, representing an increase of 16 percent and a decrease of 7 percent as compared to $6.5 million and $24.3 million in the comparable prior year periods. The increase in the three-month period ended September 30, 2010 is primarily due to manufacturing activities associated with our hearing loss and balance disorder program, higher general laboratory and funded program supply costs and higher professional, personnel and facility costs as compared to the same period in 2009.  Partially offsetting these increases are decreased manufacturing activities related to our FMD and TNFerade programs and decreased clinical costs related to the termination of the PACT trial.  The decrease in the nine-month period ended September 30, 2010 is due mainly to lower manufacturing costs during the period and to a lesser extent, clinical costs related to the termination of the PACT trial.  Manufacturing costs related to the TNFerade program decreased significantly due to the expense in 2009 associated with the termination of the Cobra Biomanufacturing Plc agreement with no corresponding costs in the comparable period in 2010.  These decreases are partially offset by increased laboratory supply costs.  

GenVec ended the third quarter of 2010 with $35.9 million in cash, cash equivalents, and investments.  

"We anticipate revenues for 2010 will be between $16.0 million and $18.0 million. We currently project our cash burn to be approximately $1.5 million per quarter," commented GenVec's Senior Vice President and Chief Financial Officer, Douglas J. Swirsky.

Conference Call Information GenVec will hold a conference call at 10:00 a.m. EST on Tuesday, November 9, 2010 to discuss the Company's strategy and third quarter results. To listen to the live conference call, please dial 877-558-0567 (U.S. or Canada) or 706-643-4980 (international) and use the following Conference ID: 17066969. An audio replay of the conference call will be available starting at 1:00 p.m. EST on November 9, 2010 through November 16, 2010. To listen to the audio replay, dial 800-642-1687 or 706-645-9291 (international) and use access code 17066969.

A live webcast of the conference call will be available on the Company's website and will be archived for 30 days. To access the webcast or the replay, go to www.genvec.com, click on "Investor Relations," and click on "Webcasts and Data."  

About GenVecGenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec uses proprietary drug discovery and development technologies to support a portfolio of product programs that address the prevention and treatment of a number of major diseases.  In collaboration with Novartis, GenVec is developing novel treatments for hearing loss and balance disorders. GenVec also develops and is evaluating the potential of TNFerade for the treatment of certain cancers and is developing vaccines for infectious diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues, operating expenses, cash burn and the focus of the Company's business plan, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.  GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to our product candidates being in early stages of development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations.  Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.  These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.GenVec, Inc.Condensed Statements of Operations(in thousands, except per share data)Three Months EndedNine Months EndedSeptember 30,September 30,2010200920102009(Unaudited)

(Unaudited)Revenues $  5,156

$  2,926

$  11,276

$  10,502Operating expenses:   Research and development

  General and administrative   Total operating expenses5,1372,3977,5344,774,719,493 16,016,626

 22,642 19,1595,102

 24,261Loss from operations   Interest income

  Interest income/(expense), net

  Other

Net loss  (2,378)(1)-

  $ (2,378)  (3,567)23-

  $ (3,562)  (11,366)324(31)

  $ (11,270)  (13,759)37(62)(268)

  $ (14,052)Basic and diluted loss per share $  (0.02)

$  (0.04)

$  (0.09)

$  (0.15)Shares used in computing basic and diluted net loss per   share129,025

101,001

125,911

93,953GenVec, Inc.Selected Balance Sheet Information(in thousands)September 30, 2010December 31, 2009(Unaudited)Cash, cash equivalents, and investments

$35,947

$10,961Working capital

32,688

7,002Total assets

40,289

13,443Stockholders' equity

32,939

7,636Investor Contact:GenVec, Inc. Douglas J. Swirsky (240) 632-5510dswirsky@genvec.com
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GenVec Receives Second-Year Funding From SAIC for HIV and Influenza Vaccine Development
2. GenVec Receives National Cancer Institute Grant to Expand Cancer Program
3. GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
4. Medtronic, Stryker, and BrainLAB Covered in New Surgical Navigation Market Research Reports Released by Millennium Research Group
5. ADVENTRX Reports Third Quarter Financial Results
6. Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2011 Financial Results
7. Medivation Reports Third Quarter 2010 Financial Results and Provides Corporate Update
8. Allied Healthcare Products Reports Narrow Loss for Quarter But Improves Year-Over-Year Performance
9. Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results
10. NOVAVAX Reports Third Quarter 2010 Financial Results
11. Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... SAN FRANCISCO , Sept. 12, 2017 /PRNewswire/ ... Lifecycle Management Solutions (VLMS), is pleased to announce ... as a member of its Board of Directors ... 2017. ValGenesis VLMS enables life science companies to ... eliminate the use of paper in this process. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, a family ... and Raleigh regions, is organizing an extended charity drive to benefit the family ... abnormality. , After struggling since birth with several health challenges, T.J. was later ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association ... standards of excellence for the field of eating disorders, announces the opening of ... 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers care ... have a waiver for care if the client has a cognitive impairment diagnosis. ... for care, is often waived, so the benefits from their insurance start immediately,” said ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
Breaking Medicine News(10 mins):